Kevin Conroy: Exact Sciences launched the Cologuard Plus test
Kevin Conroy, Chairman and CEO at Exact Sciences, shared on LinkedIn:
“This morning, Exact Sciences launched the Cologuard Plus test. With enriched sensitivity and specificity, the Cologuard Plus test more effectively detects cancers while reducing false positives, allowing more patients to avoid unnecessary colonoscopies. This is a major step forward in early detection.
A decade of dedication led to this breakthrough, reflecting our team’s relentless commitment to improving patient care. And this is just the beginning. In 2025, we will introduce two more groundbreaking innovations: Cancerguard EX, our multi-cancer early detection (MCED) test, and Oncodetect, our molecular residual disease (MRD) test.
I’m incredibly proud of the team’s hard work and I couldn’t be more excited for the future!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023